Trending...
- Mars Branded Skittles® and Starburst Cotton Candy to Launch!
- Waste Management Shareholder News: Robbins LLP is Investigating Waste Management, Inc. (WM) on Behalf of Shareholders
- James Postrasija, CEO of Order Food Online on Platform Features/Benefits
SAN JOSE, Calif. - Californer -- CPC Scientific Inc., a leading global peptide CRDMO (Contract Research, Development, and Manufacturing Organization) has invested in a new peptide API (Active Pharmaceutical Ingredient) manufacturing site, bringing many new jobs to Rocklin, California. The 41,000 sq ft facility located at 3880 Atherton Rd, Rocklin, CA 95765 will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity and will diversify CPC Scientific's supply chain.
"CPC Scientific is entering an exciting period of growth and innovation for peptide and oligonucleotide therapeutic development and manufacturing, and we will continue to provide therapeutic APIs to pharmaceutical and biotech companies around the world. We are very pleased to partner with the City of Rocklin, California to bring manufacturing and Life-Science jobs to local American workers," said Shawn Lee, Ph.D., CEO.
Expanding CPC Scientific's manufacturing footprint in North America enables them to continue to produce innovative peptide products while providing additional capacity to specialty peptide APIs more rapidly.
More on The Californer
Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years. For over two decades, CPC Scientific has been a reliable partner for its clients all over the world including multinational pharmaceutical companies, biotech companies, and academic institutions by providing value-added one-stop-shop development and manufacturing services to support their clinical trials. CPC Scientific has been successfully supplying commercialized APIs to their clients in the U.S., Europe, Australia, Japan, and China for their peptide-based drugs and medical devices. By expanding their GMP manufacturing footprint, the CRDMO will enable their clients and partners to have multiple geographic options to ensure a secure API supply chain.
"We have helped many of our clients to bring an innovative drug into the market from a concept. With the new Rocklin site, we believe we will be able to contribute more especially to the Northern American market and we will continue making our efforts with our decades of peptide synthesis expertise to help our clients to save lives and improve human health worldwide," said Shawn Lee, Ph.D.
More on The Californer
The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023. With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.
About CPC Scientific.
Founded in 2001, CPC Scientific is a globally recognized and leading CRDMO specializing in synthetic peptide production, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing and is proudly supplying commercial APIs to our partners all over the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous multi-Kg batch size projects. With an emphasis on technology, innovation, and experience, we are proud to have facilities inspected by many government agencies including U.S. Food and Drug Administration (FDA).
"CPC Scientific is entering an exciting period of growth and innovation for peptide and oligonucleotide therapeutic development and manufacturing, and we will continue to provide therapeutic APIs to pharmaceutical and biotech companies around the world. We are very pleased to partner with the City of Rocklin, California to bring manufacturing and Life-Science jobs to local American workers," said Shawn Lee, Ph.D., CEO.
Expanding CPC Scientific's manufacturing footprint in North America enables them to continue to produce innovative peptide products while providing additional capacity to specialty peptide APIs more rapidly.
More on The Californer
- INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in 17 Education & Technology Group Inc. with Losses of $100,000 to Contact the Firm
- Money Today Korea Selects Grinergy as a 2022 R&D Innovation Grand Prize Winner
- Virgin Orbit Successfully Launches 'Straight Up' Mission
- INVESTOR DEADLINE: Inotiv, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action – NOTV
- Milloret LTD To Offer Premium International SEO Services
Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years. For over two decades, CPC Scientific has been a reliable partner for its clients all over the world including multinational pharmaceutical companies, biotech companies, and academic institutions by providing value-added one-stop-shop development and manufacturing services to support their clinical trials. CPC Scientific has been successfully supplying commercialized APIs to their clients in the U.S., Europe, Australia, Japan, and China for their peptide-based drugs and medical devices. By expanding their GMP manufacturing footprint, the CRDMO will enable their clients and partners to have multiple geographic options to ensure a secure API supply chain.
"We have helped many of our clients to bring an innovative drug into the market from a concept. With the new Rocklin site, we believe we will be able to contribute more especially to the Northern American market and we will continue making our efforts with our decades of peptide synthesis expertise to help our clients to save lives and improve human health worldwide," said Shawn Lee, Ph.D.
More on The Californer
- Summit County Pest Control Is Going After The American Cockroach
- How do I change my name on Delta Airlines?
- New Highland Cow Decor-Highland Cow Art
- Lieff Cabraser LLP, Stiegler Law Firm LLC, and Robert B. Landry III PLC File Federal Lawsuit Against Apple, Inc. for Failure to Pay Overtime and Other Lawfully Required Compensation to Apple Solutions Consultants
- California: Governor Newsom Grants Executive Clemency 7.1.22
The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023. With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.
About CPC Scientific.
Founded in 2001, CPC Scientific is a globally recognized and leading CRDMO specializing in synthetic peptide production, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing and is proudly supplying commercial APIs to our partners all over the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous multi-Kg batch size projects. With an emphasis on technology, innovation, and experience, we are proud to have facilities inspected by many government agencies including U.S. Food and Drug Administration (FDA).
Source: CPC Scientific Inc.
0 Comments
Latest on The Californer
- INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Riskified Ltd. with Losses of $100,000 to Contact the Firm
- Telegraph Hill Partners Raises $525M Fifth Fund for New Life Science and Healthcare Investments
- EA SPORTS™ F1® 22 Launches Worldwide Today
- Diving Into Informative Television With 'A Hot Set's'- 'Statement'
- San Francisco: Mayor London Breed Statement on State Budget Includes Investments of Nearly $55 Million in Community Projects
- Governor Newsom Signs Into Law Strongest Extended Producer Responsibility Legislation in the U.S.
- California: Governor Newsom Signs Legislation Cutting Harmful Plastic Pollution to Protect Communities, Oceans and Animals
- TikTok Marketing Strategy-Boost Your Business With TikTok
- Governor Newsom Signs Budget Putting Money Back in Californians' Pockets and Investing in State's Future
- Aimmune Therapeutics to Present New Data for PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022
- San Francisco World Spirits Competition Announces Premium Winners at Inaugural Awards Gala
- Best AI Copywriter-The Future Of Copy-writing Is Now
- San Jose: Notice of CEQA Posting: Addendum to the 4300 Stevens Creek Boulevard Mixed-Use Project
- Indie Brand Vow Beauty Enters Walmart
- INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Abbott Laboratories with Losses of $100,000 to Contact the Firm
- 360 VUZ Immersive Video App Wins Webit Founders Games Finalist USA - English USA - English
- San Jose: Notice of CEQA Posting: Addendum to the 1605 Industrial Avenue Redevelopment Project
- Building a Better Long Beach
- James Postrasija, CEO of Order Food Online on Platform Features/Benefits
- Disney Good Neighbor Hotel Lulu is Open for the Summer